Expression of metastasis‑associated lung adenocarcinoma transcript 1 long non‑coding RNA in�vitro and in patients with non‑small cell lung cancer

Abstract

The present study aimed to investigate the association between the expression of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) long non-coding RNA (lncRNA) and the recurrence of non-small cell lung cancer (NSCLC) and to elucidate the potential mechanisms of MALAT1 . Between 1 June 1, 2010 and December 30, 2016, NSCLC tumor tissues and adjacent non-cancerous tissues were obtained from 120 patients with NSCLC, who had undergone surgical resection at Taizhou Hospital of Wenzhou Medical University (Linhai, China). The total RNA of tissues and cells were extracted and the expression of MALAT1 was determined using a wound healing assay and reverse transcription quantitative polymerase chain reaction. In addition, MALAT1 expression in A549 cells was silenced using small interfering RNA. The proliferation, migration and invasion of cells were then assessed using a CellTiter 96 kit and Transwell assays. MALAT1 expression was significantly increased in NSCLC samples compared with expression in adjacent non-cancerous tissues. Furthermore, the expression of MALAT1 in patients with NSCLC that exhibited recurrence was markedly higher than in those that did not. The results of the present study also demonstrated significant associations between high expression of MALAT1 and female sex, Tumor-Node-Metastasis advanced stage, vessel invasion, pathological differentiation and recurrence of patients with NSCLC. The proliferative, migratory and invasive abilities of MALAT1-silenced A549 cells were significantly decreased compared with those of control cells. MALAT1 expression was significantly increased in NSCLC tissues and was revealed to serve a role in the progression of NSCLC.

Genetic Variants of lncRNA MALAT1 Exert Diverse Impacts on the Risk and Clinicopathologic Characteristics of Patients with Hepatocellular Carcinoma

“…HCC is characterized by its propensity for vascular invasion, and MALAT1 was reported to promote invasion by HCC cells. In non-small cell lung cancer (NSCLC), higher MALAT1 expression was significantly related to female sex, TMN stage, vessel invasion, and recurrence [41]. In the current study, a novel genetic variant, viz., rs1194338, in the promoter region of MALAT1 was evaluated, and we found that female HCC patients with the MALAT1 rs1194338 A allele were significantly associated with a decreased risk of developing vascular invasion compared to those with the C allele.…”

MALAT1: a potential biomarker in cancer

“…Recently, aberrant expression of MALAT1 has been reported to be associated with cancer prognosis markedly (Table 4). In NSCLC, a higher MALAT1 expression significantly related to female sex ( P =0.019), TNM stage ( P =0.016), vessel invasion ( P =0.032), pathological differentiation ( P =0.013), and recurrence ( P =0.006) 84. Additionally, cooverexpression of MALAT1, NEAT1, and Oct4 in lung cancer has been shown to be an independent prognostic factor for poor outcome 85.…”

Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis

“…Non-small cell lung cancer (NSCLC) accounts for 80–85% of all patients with lung cancer, which is also the most malignant carcinoma among men and women, with an incidence higher than the combined incidence of breast, cervical, and colorectal cancers ( Spiro and Porter, 2002 ; Maher et al, 2012 ). Although prominent progress in early diagnosis and treatment methods, 5-year relative overall survival (OS) rate is less than 20% ( Boolell et al, 2015 ; Lin et al, 2018 ). For inoperable cancer patients and surgical patients chemotherapy remains the most important complementary treatment, and platinum is mild in the treatment of advanced NSCLC ( Song et al, 2014 ).…”